RecruitingPhase 2NCT06176508

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis

Sponsor

Hansoh BioMedical R&D Company

Enrollment

160 participants

Start Date

Feb 26, 2024

Study Type

INTERVENTIONAL

Conditions

Psoriatic Arthritis

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HS-10374, a drug called HS-10374-matched placebo tablets, and others for people with psoriatic arthritis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHS-10374

Administered orally QD for 16 weeks

DRUGHS-10374-matched placebo tablets

Administered orally QD for 16 weeks

DRUGTofacitinib 5Mg Tab,Oral

Administered orally BID for 16 weeks

Locations(1)

Huashan Hospital affiliated to Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06176508

Related Trials

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT0381634552 locations

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT0686402655 locations